Get started
VERTEX PHARMACEUTICALS INCVERTEX PHARMACEUTICALS INCVERTEX PHARMACEUTICALS INC

VERTEX PHARMACEUTICALS INC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

VRTX chart


Full chart

Key facts today


UBS has lowered its price target on Vertex Pharmaceuticals from $586 to $583, while continuing to maintain a 'Buy' rating.
Analyze the impactAnalyze the impact

VRTX upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪116.83 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.00 EUR
Net income (FY)
‪−517.38 M‬ EUR
Revenue (FY)
‪10.65 B‬ EUR
Shares float
‪256.19 M‬
Beta (1Y)
1.26

About Vertex Pharmaceuticals Incorporated


Sector
Health Technology
CEO
Reshma Kewalramani
Headquarters
Boston
Website
vrtx.com
Founded
1989
FIGI
BBG00GQ6SBQ9
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

VRTX news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Sparks


Curated watchlists where VRTX is featured.

See all sparks 

Frequently Asked Questions


The current price of VRTX is 434.10 EUR — it has decreased by −2.17% in the past 24 hours. Watch VERTEX PHARMACEUTICALS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on VIE exchange VERTEX PHARMACEUTICALS INC stocks are traded under the ticker VRTX.
VRTX stock has fallen by −2.57% compared to the previous week, the month change is a 11.27% rise, over the last year VERTEX PHARMACEUTICALS INC has showed a 11.69% increase.
We've gathered analysts' opinions on VERTEX PHARMACEUTICALS INC future price: according to them, VRTX price has a max estimate of 592.42 EUR and a min estimate of 317.89 EUR. Watch VRTX chart and read a more detailed VERTEX PHARMACEUTICALS INC stock forecast: see what analysts think of VERTEX PHARMACEUTICALS INC and suggest that you do with its stocks.
VRTX reached its all-time high on Nov 11, 2024 with the price of 487.50 EUR, and its all-time low was 104.50 EUR and was reached on May 24, 2017. View more price dynamics on VRTX chart.
See other stocks reaching their highest and lowest prices.
VRTX stock is 2.70% volatile and has beta coefficient of 1.26. Track VERTEX PHARMACEUTICALS INC stock price on the chart and check out the list of the most volatile stocks — is VERTEX PHARMACEUTICALS INC there?
Today VERTEX PHARMACEUTICALS INC has the market capitalization of ‪112.93 B‬, it has decreased by −6.44% over the last week.
Yes, you can track VERTEX PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
VERTEX PHARMACEUTICALS INC is going to release the next earnings report on Apr 30, 2025. Keep track of upcoming events with our Earnings Calendar.
VRTX earnings for the last quarter are 3.84 EUR per share, whereas the estimation was 3.88 EUR resulting in a −0.90% surprise. The estimated earnings for the next quarter are 4.09 EUR per share. See more details about VERTEX PHARMACEUTICALS INC earnings.
VERTEX PHARMACEUTICALS INC revenue for the last quarter amounts to ‪2.81 B‬ EUR, despite the estimated figure of ‪2.69 B‬ EUR. In the next quarter, revenue is expected to reach ‪2.75 B‬ EUR.
VRTX net income for the last quarter is ‪881.94 M‬ EUR, while the quarter before that showed ‪938.92 M‬ EUR of net income which accounts for −6.07% change. Track more VERTEX PHARMACEUTICALS INC financial stats to get the full picture.
No, VRTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, VRTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade VERTEX PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So VERTEX PHARMACEUTICALS INC technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating VERTEX PHARMACEUTICALS INC stock shows the buy signal. See more of VERTEX PHARMACEUTICALS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.